Alexander E Merkler1, Gino Gialdini2, Shadi Yaghi2, Peter M Okin2, Costantino Iadecola2, Babak B Navi2, Hooman Kamel2. 1. From the Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute (A.E.M., G.G., C.I., B.B.N., H.K.), Department of Neurology (A.E.M., C.I., B.B.N., H.K.), and Division of Cardiology (P.M.O.), Weill Cornell Medicine, New York; and Department of Neurology, the Warren Alpert Medical School of Brown University, Providence, RI (S.Y.). alm9097@med.cornell.edu. 2. From the Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute (A.E.M., G.G., C.I., B.B.N., H.K.), Department of Neurology (A.E.M., C.I., B.B.N., H.K.), and Division of Cardiology (P.M.O.), Weill Cornell Medicine, New York; and Department of Neurology, the Warren Alpert Medical School of Brown University, Providence, RI (S.Y.).
Abstract
BACKGROUND AND PURPOSE: We sought to evaluate the real-world rate of safety outcomes after patent foramen ovale (PFO) closure in patients with ischemic stroke or transient ischemic attack (TIA). METHODS: We performed a retrospective cohort study using administrative claims data on all hospitalizations from 2005 to 2013 in New York, California, and Florida. Using International Classification of Diseases, Ninth Revision, Clinical Modification codes, we identified patients who underwent percutaneous transcatheter PFO closure within 1 year of ischemic stroke or TIA. Our outcome was an adverse event occurring during the hospitalization for PFO closure, defined as in prior studies as atrial fibrillation or flutter, cardiac tamponade, pneumothorax, hemothorax, a vascular access complication, or death. Crude rates were reported with exact confidence intervals. RESULTS: We identified 1887 patients who underwent PFO closure after ischemic stroke or TIA. The rate of any adverse outcome during the hospitalization for PFO closure was 7.0% (95% confidence interval [CI], 5.9%-8.2%). Rates of adverse outcomes varied by age and type of preceding cerebrovascular event. In patients >60 years of age, the rate of adverse outcomes was 10.9% (95% CI, 8.6%-13.6%) versus 4.9% (95% CI, 3.8%-6.3%) in patients ≤60 years of age. The rate of adverse outcomes was 9.9% (95% CI, 7.3%-12.5%) in patients with preceding ischemic stroke versus 5.9% (95% CI, 4.7%-7.1%) after TIA. CONCLUSIONS: Approximately 1 in 14 patients who underwent percutaneous transcatheter PFO closure after ischemic stroke or TIA experienced a serious periprocedural adverse outcome or death. The risk of adverse outcomes was highest in older patients and in those with preceding ischemic stroke.
BACKGROUND AND PURPOSE: We sought to evaluate the real-world rate of safety outcomes after patent foramen ovale (PFO) closure in patients with ischemic stroke or transient ischemic attack (TIA). METHODS: We performed a retrospective cohort study using administrative claims data on all hospitalizations from 2005 to 2013 in New York, California, and Florida. Using International Classification of Diseases, Ninth Revision, Clinical Modification codes, we identified patients who underwent percutaneous transcatheter PFO closure within 1 year of ischemic stroke or TIA. Our outcome was an adverse event occurring during the hospitalization for PFO closure, defined as in prior studies as atrial fibrillation or flutter, cardiac tamponade, pneumothorax, hemothorax, a vascular access complication, or death. Crude rates were reported with exact confidence intervals. RESULTS: We identified 1887 patients who underwent PFO closure after ischemic stroke or TIA. The rate of any adverse outcome during the hospitalization for PFO closure was 7.0% (95% confidence interval [CI], 5.9%-8.2%). Rates of adverse outcomes varied by age and type of preceding cerebrovascular event. In patients >60 years of age, the rate of adverse outcomes was 10.9% (95% CI, 8.6%-13.6%) versus 4.9% (95% CI, 3.8%-6.3%) in patients ≤60 years of age. The rate of adverse outcomes was 9.9% (95% CI, 7.3%-12.5%) in patients with preceding ischemic stroke versus 5.9% (95% CI, 4.7%-7.1%) after TIA. CONCLUSIONS: Approximately 1 in 14 patients who underwent percutaneous transcatheter PFO closure after ischemic stroke or TIA experienced a serious periprocedural adverse outcome or death. The risk of adverse outcomes was highest in older patients and in those with preceding ischemic stroke.
Authors: Stephan Windecker; Andreas Wahl; Krassen Nedeltchev; Marcel Arnold; Markus Schwerzmann; Christian Seiler; Heinrich P Mattle; Bernhard Meier Journal: J Am Coll Cardiol Date: 2004-08-18 Impact factor: 24.094
Authors: Nathaniel W Taggart; Guy S Reeder; Ryan J Lennon; Joshua P Slusser; Monique A Freund; Allison K Cabalka; Frank Cetta; Donald J Hagler Journal: Catheter Cardiovasc Interv Date: 2016-03-29 Impact factor: 2.692
Authors: Ignacio Inglessis; Sammy Elmariah; Pablo A Rengifo-Moreno; Ronan Margey; Caitlin O'Callaghan; Ignacio Cruz-Gonzalez; Suzanne Baron; Praveen Mehrotra; Timothy C Tan; Judy Hung; Zareh N Demirjian; Ferdinando S Buonanno; MingMing Ning; Scott B Silverman; Roberto J Cubeddu; Eugene Pomerantsev; Robert M Schainfeld; G William Dec; Igor F Palacios Journal: JACC Cardiovasc Interv Date: 2013-11 Impact factor: 11.195
Authors: John D Carroll; Jeffrey L Saver; David E Thaler; Richard W Smalling; Scott Berry; Lee A MacDonald; David S Marks; David L Tirschwell Journal: N Engl J Med Date: 2013-03-21 Impact factor: 91.245
Authors: Gregory Y H Lip; Deirdre A Lane; Radosław Lenarczyk; Giuseppe Boriani; Wolfram Doehner; Laura A Benjamin; Marc Fisher; Deborah Lowe; Ralph L Sacco; Renate Schnabel; Caroline Watkins; George Ntaios; Tatjana Potpara Journal: Eur Heart J Date: 2022-07-07 Impact factor: 35.855
Authors: Laura Oliva; Eric Horlick; Bo Wang; Ella Huszti; Ruth Hall; Lusine Abrahamyan Journal: BMC Med Inform Decis Mak Date: 2022-04-06 Impact factor: 2.796